CABALETTA BIO, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
CABALETTA BIO, INC. (CABA) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $160.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-13
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $94.00K, a 32.86% decline year-over-year.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $140.00K, a 84.21% increase year-over-year.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $291.00K, a 8.18% increase from fiscal 2024.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $269.00K, a 149.07% increase from fiscal 2023.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $108.00K, a 42.11% increase from fiscal 2022.
- CABALETTA BIO, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $76.00K, a 7.04% increase from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $160.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $94.00K derived: sum of 2 quarters · filed 2026-03-23 | $291.00K 10-K · filed 2026-03-23 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $197.00K 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $197.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $140.00K derived: sum of 2 quarters · filed 2026-03-23 | $269.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $129.00K 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $129.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $76.00K derived: sum of 2 quarters · filed 2025-03-31 | $108.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $32.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $32.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $36.00K derived: sum of 2 quarters · filed 2024-03-21 | $76.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $40.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $40.00K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $25.00K derived: sum of 2 quarters · filed 2023-03-16 | $71.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $46.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $46.00K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $29.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |